Table 2.
List of immunotoxins investigated for multiple myeloma.
| Drug name | Target | Effector moiety | Development state | Clinical trial | Treatment regimen | Status | References |
|---|---|---|---|---|---|---|---|
| TAK-169 | CD38 | SLTA (deimmunized) | Clinical | NCT04017130; phase 1 | TAK-169 mono | Recruiting | (109, 110) |
| 1053-PE38 | CD38 | Pseudomonas exotoxin A 38 kDa fragment (PE38) | Preclinical | - | - | - | (117) |
| IB4/saporin-S6 | CD38 | Saporin-S6 | Preclinical | - | - | - | (119) |
| OKT10-Sap | CD38 | Saporin | Clinical | Cancer Research UK trial; phase 1 | OKT10-Sap mono | - | (120) |
| HB7-blocked ricin | CD38 | Ricin | Preclinical | - | - | - | (121) |
| ch128.1Av/b-SO6 (anti-hTfR IgG3-Av/b-SO6) | CD71 | Biotinylated saporin 6 | Preclinical | - | - | - | (122) |
| 2L-Rap-hLL1-γ4P | CD74 | Frog Rnase | Preclinical | - | - | - | (123) |
| B-B2-saporinB-B4-saporin | CD138 | Saporin | Preclinical | - | - | - | (124) |
| LMB-70 LMB-75 LMB-38 |
BCMA (CD269) | Pseudomonas exotoxin A domain III (PE24) | Preclinical | - | - | - | (125–127) |
| HM1.24-ETA' | CD317 | Pseudomonas aeruginosa exotoxin A (ETA) | Preclinical | - | - | - | (128) |
| rGel/BLyS | BAFF-R (CD268), TACI (CD267) or BCMA (CD269) | Gelonin, recombinant | Preclinical | - | - | - | (129) |
mono, monotherapy..